Sanctuary Advisors LLC Has $2.17 Million Holdings in Humana Inc. (NYSE:HUM)

Sanctuary Advisors LLC increased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,533 shares of the insurance provider's stock after purchasing an additional 1,258 shares during the period. Sanctuary Advisors LLC's holdings in Humana were worth $2,165,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. FMR LLC grew its stake in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after acquiring an additional 643,291 shares during the period. Thrivent Financial for Lutherans grew its stake in Humana by 55.6% in the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider's stock valued at $190,145,000 after acquiring an additional 214,535 shares during the period. Retirement Systems of Alabama grew its stake in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock valued at $55,563,000 after acquiring an additional 192,801 shares during the period. Pzena Investment Management LLC grew its stake in Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after acquiring an additional 187,903 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new position in Humana in the third quarter valued at about $50,102,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.32% of the stock is owned by company insiders.

Humana Price Performance

Shares of NYSE HUM opened at $255.77 on Monday. The business's 50 day moving average price is $269.41 and its two-hundred day moving average price is $289.61. The company has a market cap of $30.80 billion, a PE ratio of 25.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. The ex-dividend date is Friday, March 28th. Humana's payout ratio is 35.58%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wells Fargo & Company decreased their target price on Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. TD Cowen boosted their target price on Humana from $261.00 to $268.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. JPMorgan Chase & Co. cut their price target on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Humana has an average rating of "Hold" and a consensus target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.